Suppression of PI3K/mTOR pathway rescues LLC cells from cell death induced by hypoxia

被引:26
作者
Hamanaka, Y
Mukai, M
Shimamura, M
Kitagawa, T
Nishida, T
Isohashi, F
Ito, T
Nishizawa, Y
Tatsuta, M
Matsuda, H
Inoue, M [1 ]
机构
[1] Osaka Med Ctr Canc & Cardiovasc Dis, Dept Biochem, Osaka, Japan
[2] Osaka Med Ctr Canc & Cardiovasc Dis, Dept Pathol, Osaka, Japan
[3] Osaka Med Ctr Canc & Cardiovasc Dis, Dept Gastrointestinal Oncol, Osaka, Japan
[4] Osaka Univ, Grad Sch Med, Dept Regenerat Med, Osaka, Japan
关键词
hypoxia resistance; cancer; PI3K; mTOR; S6K; S6; ATP; necrosis; cell cycle;
D O I
10.1016/j.bbrc.2005.02.163
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cancer cells in solid tumors are challenged by various microenvironmental stresses, including hypoxia, and cancer cells in hypoxic regions are resistant to current cancer therapies. To investigate the mechanism of resistance to hypoxia in cancer cells, we examined mouse Lewis lung carcinoma (LLC) cells, which died due to necrosis at high density under hypoxic but not under normoxic conditions. Levels of mammalian target of rapamycin (mTOR), a central regulator of cellular energy, are reported to be suppressed in hypoxia. We found that phosphorylation of two molecules downstream to it, ribosomal p70 S6 kinase (S6K) and ribosomal protein S6, was markedly suppressed by hypoxia. Overexpression of the active form of S6K increased the sensitivity of LLC cells to hypoxia. On the other hand, inhibition of PI3K or mTOR dramatically reduced hypoxia-induced cell death under hypoxic conditions. Under hypoxic conditions, blockade of the PI3K or mTOR pathway increased levels of intracellular ATP and delayed decreases in pH and glucose level in culture medium, without affecting the cell cycle. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:318 / 326
页数:9
相关论文
共 33 条
[1]   A novel hypoxia-inducible factor-independent hypoxic response regulating mammalian target of rapamycin and its targets [J].
Arsham, AM ;
Howell, JJ ;
Simon, MC .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (32) :29655-29660
[2]   Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma [J].
Atkins, MB ;
Hidalgo, M ;
Stadler, WM ;
Logan, TF ;
Dutcher, JP ;
Hudes, GR ;
Park, Y ;
Lion, SH ;
Marshall, B ;
Boni, JP ;
Dukart, G ;
Sherman, ML .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) :909-918
[3]   The TOR pathway: A target for cancer therapy [J].
Bjornsti, MA ;
Houghton, PJ .
NATURE REVIEWS CANCER, 2004, 4 (05) :335-348
[4]   Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells [J].
Boulay, A ;
Zumstein-Mecker, S ;
Stephan, C ;
Beuvink, I ;
Zilbermann, F ;
Haller, R ;
Tobler, S ;
Heusser, C ;
O'Reilly, T ;
Stolz, B ;
Marti, A ;
Thomas, G ;
Lane, HA .
CANCER RESEARCH, 2004, 64 (01) :252-261
[5]   Drosophila's insulin/P13-kinase pathway coordinates cellular metabolism with nutritional conditions [J].
Britton, JS ;
Lockwood, WK ;
Li, L ;
Cohen, SM ;
Edgar, BA .
DEVELOPMENTAL CELL, 2002, 2 (02) :239-249
[6]   Exploiting tumour hypoxia in cancer treatment [J].
Brown, JM ;
William, WR .
NATURE REVIEWS CANCER, 2004, 4 (06) :437-447
[7]   Ribosomal S6 kinase signaling and the control of translation [J].
Dufner, A ;
Thomas, G .
EXPERIMENTAL CELL RESEARCH, 1999, 253 (01) :100-109
[8]  
Durand RE, 1998, CANCER RES, V58, P3547
[9]  
Eguchi Y, 1997, CANCER RES, V57, P1835
[10]   Hypoxia and nitric oxide treatment confer tolerance to glucose starvation in a 5′-AMP-activated protein kinase-dependent manner [J].
Esumi, H ;
Izuishi, K ;
Kato, K ;
Hashimoto, K ;
Kurashima, Y ;
Kishimoto, A ;
Ogura, T ;
Ozawa, T .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (36) :32791-32798